Vaxcyte Stock Investor Sentiment
| PCVX Stock | USD 99.38 4.26 4.11% |
Slightly above 56% of Vaxcyte's investor base is looking to short. The analysis of the overall investor sentiment regarding Vaxcyte suggests that many traders are alarmed. Vaxcyte's investing sentiment can be driven by a variety of factors including economic data, Vaxcyte's earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
44
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Vaxcyte's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Vaxcyte.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Vaxcyte Historical Sentiment
Although Vaxcyte's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Vaxcyte, such as negative comments on social media and news outlets, may cause fear in the market and push Vaxcyte's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Vaxcyte.
Vaxcyte |
Vaxcyte Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vaxcyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vaxcyte Historical Investor Sentiment
Investor biases related to Vaxcyte's public news can be used to forecast risks associated with an investment in Vaxcyte. The trend in average sentiment can be used to explain how an investor holding Vaxcyte can time the market purely based on public headlines and social activities around Vaxcyte. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vaxcyte's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vaxcyte and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Vaxcyte news discussions. The higher the estimate score, the more favorable the investor's outlook on Vaxcyte.
Far too much social signal, news, headlines, and media speculation about Vaxcyte that are available to investors today. That information is available publicly through Vaxcyte media outlets and privately through word of mouth or via Vaxcyte internal channels. However, regardless of the origin, that massive amount of Vaxcyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vaxcyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaxcyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaxcyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaxcyte alpha.
Vaxcyte Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 3006 shares by Guggenhime Andrew of Vaxcyte at 79.135 subject to Rule 16b-3 | 08/19/2024 |
2 | Disposition of 15000 shares by Pickering Grant of Vaxcyte at 2.03 subject to Rule 16b-3 | 08/23/2024 |
3 | Peering Into Vaxcytes Recent Short Interest - Benzinga | 08/27/2024 |
4 | Disposition of 10000 shares by Wassil Jim of Vaxcyte at 2.42 subject to Rule 16b-3 | 09/16/2024 |
5 | Disposition of 256 shares by Loxam Teri of Vaxcyte at 117.51 subject to Rule 16b-3 | 09/17/2024 |
6 | Acquisition by Guggenhime Andrew of 8000 shares of Vaxcyte at 5.35 subject to Rule 16b-3 | 09/20/2024 |
7 | Disposition of 1030 shares by Eydelman Mikhail of Vaxcyte at 115.012 subject to Rule 16b-3 | 10/01/2024 |
8 | Disposition of tradable shares by Eydelman Mikhail of Vaxcyte at 111.68 subject to Rule 16b-3 | 10/07/2024 |
9 | Disposition of 310 shares by Pickering Grant of Vaxcyte at 107.268 subject to Rule 16b-3 | 10/08/2024 |
10 | Vaxcyte CEO Grant Pickering sells shares worth over 775,000 | 10/09/2024 |
11 | Disposition of 5886 shares by Guggenhime Andrew of Vaxcyte at 116.191 subject to Rule 16b-3 | 10/18/2024 |
12 | Acquisition by Guggenhime Andrew of 19108 shares of Vaxcyte at 20.93 subject to Rule 16b-3 | 10/25/2024 |
13 | Disposition of 1585 shares by Wassil Jim of Vaxcyte at 5.35 subject to Rule 16b-3 | 10/28/2024 |
14 | Should You Consider Investing in Vaxcyte | 11/01/2024 |
15 | Vaxcyte Inc Reports Q3 2024 Net Loss of 103. ... | 11/05/2024 |
16 | Decoding Vaxcyte Inc A Strategic SWOT Insight | 11/06/2024 |
17 | Needham Company LLC Reiterates Buy Rating for Vaxcyte | 11/08/2024 |
18 | Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs | 11/12/2024 |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.